AU2001257410B8 - Method of identifying and producing antigen peptides and use thereof as vaccines - Google Patents

Method of identifying and producing antigen peptides and use thereof as vaccines Download PDF

Info

Publication number
AU2001257410B8
AU2001257410B8 AU2001257410A AU2001257410A AU2001257410B8 AU 2001257410 B8 AU2001257410 B8 AU 2001257410B8 AU 2001257410 A AU2001257410 A AU 2001257410A AU 2001257410 A AU2001257410 A AU 2001257410A AU 2001257410 B8 AU2001257410 B8 AU 2001257410B8
Authority
AU
Australia
Prior art keywords
epitope
antigen
virus
vaccine
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001257410A
Other languages
English (en)
Other versions
AU2001257410B9 (en
AU2001257410B2 (en
AU2001257410A1 (en
Inventor
David C. Diamond
Xiang-Dong Lei
John J. L. Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/561,074 external-priority patent/US6861234B1/en
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of AU2001257410A1 publication Critical patent/AU2001257410A1/en
Assigned to MANNKIND CORPORATION reassignment MANNKIND CORPORATION Request for Assignment Assignors: CTL IMMUNO THERAPIES CORP.
Publication of AU2001257410B2 publication Critical patent/AU2001257410B2/en
Publication of AU2001257410B9 publication Critical patent/AU2001257410B9/en
Priority to AU2006246500A priority Critical patent/AU2006246500B2/en
Application granted granted Critical
Publication of AU2001257410B8 publication Critical patent/AU2001257410B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
AU2001257410A 2000-04-28 2001-04-27 Method of identifying and producing antigen peptides and use thereof as vaccines Ceased AU2001257410B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006246500A AU2006246500B2 (en) 2000-04-28 2006-11-24 Epitope synchronization in antigen presenting cells

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US56157200A 2000-04-28 2000-04-28
US56157100A 2000-04-28 2000-04-28
US56046500A 2000-04-28 2000-04-28
US09/560,465 2000-04-28
US09/561,074 2000-04-28
US09/561,571 2000-04-28
US09/561,572 2000-04-28
US09/561,074 US6861234B1 (en) 2000-04-28 2000-04-28 Method of epitope discovery
PCT/US2001/013806 WO2001082963A2 (en) 2000-04-28 2001-04-27 Method of identifying and producing antigen peptides and use thereof as vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006246500A Division AU2006246500B2 (en) 2000-04-28 2006-11-24 Epitope synchronization in antigen presenting cells

Publications (4)

Publication Number Publication Date
AU2001257410A1 AU2001257410A1 (en) 2002-01-31
AU2001257410B2 AU2001257410B2 (en) 2006-08-24
AU2001257410B9 AU2001257410B9 (en) 2006-10-05
AU2001257410B8 true AU2001257410B8 (en) 2006-12-21

Family

ID=27504814

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001257410A Ceased AU2001257410B8 (en) 2000-04-28 2001-04-27 Method of identifying and producing antigen peptides and use thereof as vaccines
AU5741001A Pending AU5741001A (en) 2000-04-28 2001-04-27 Epitope synchronization in antigen presenting cells
AU2010251790A Ceased AU2010251790B2 (en) 2000-04-28 2010-12-14 Epitope synchronization in antigen presenting cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU5741001A Pending AU5741001A (en) 2000-04-28 2001-04-27 Epitope synchronization in antigen presenting cells
AU2010251790A Ceased AU2010251790B2 (en) 2000-04-28 2010-12-14 Epitope synchronization in antigen presenting cells

Country Status (12)

Country Link
US (1) US20070269464A1 (enExample)
EP (4) EP2248910A1 (enExample)
JP (1) JP2003535824A (enExample)
CN (1) CN1440462A (enExample)
AT (1) ATE474931T1 (enExample)
AU (3) AU2001257410B8 (enExample)
CA (1) CA2405363A1 (enExample)
DE (1) DE60142615D1 (enExample)
DK (1) DK1276896T3 (enExample)
ES (1) ES2347762T3 (enExample)
NZ (1) NZ521715A (enExample)
WO (1) WO2001082963A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6773695B2 (en) 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
EP1595548A3 (en) * 2001-03-07 2006-02-22 Mannkind Corporation Anti-neovasculature preparations for treating cancer
WO2002069907A2 (en) * 2001-03-07 2002-09-12 Mannkind Corporation Anti-neovasculature preparations for cancer
EP1752160A3 (en) 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
AU2008229888B2 (en) * 2001-11-07 2012-07-05 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
EP1545610A4 (en) * 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
JP4914990B2 (ja) 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
ATE496129T1 (de) 2003-07-22 2011-02-15 Ludwig Inst Cancer Res Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
NZ587601A (en) * 2005-06-17 2012-05-25 Mannkind Corp Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
EP2385059A3 (en) * 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
CA2643337C (en) * 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with ctls and cytokines
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
CA2665816C (en) 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CN101246176B (zh) * 2007-02-13 2013-06-05 许洋 鳞状细胞癌抗原阴性宫颈癌血清蛋白质检测的质谱试剂及其制备方法
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
JP5906090B2 (ja) 2009-02-17 2016-04-20 コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ 癌の診断のための方法およびキットならびに治療価の推定
CA3040276A1 (en) 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
WO2012031076A1 (en) * 2010-09-02 2012-03-08 Ludwig Institute For Cancer Research, Ltd. Recombinant trypanosoma cruzi cells useful as anti-cancer immune agents
HK1199404A1 (en) * 2011-05-26 2015-07-03 Geneius Biotechnology Investments, Llc Modulated immunodominance therapy
CN107817348A (zh) * 2012-09-05 2018-03-20 亚利桑那州评议委员会,亚利桑那州法人团体,代理和代表亚利桑那州立大学 发现治疗靶标的方法
MX428954B (es) * 2013-03-15 2025-11-13 Univ Pennsylvania Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana.
EP3524262A1 (en) * 2013-11-01 2019-08-14 Pfizer Inc Vectors for expression of prostate-associated antigens
CN104761644A (zh) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
CN103837688A (zh) * 2014-03-27 2014-06-04 吉林农业大学 一种检测犬猫弓形虫抗体的间接elisa试剂盒
US20170266269A1 (en) * 2014-03-28 2017-09-21 University Of Washington Through Its Center For Commercialization Methods of identifying antigens for vaccines
CN113403338B (zh) 2014-03-28 2025-07-15 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
CN104142401B (zh) * 2014-07-25 2016-04-20 北京普恩光德生物科技开发有限公司 膀胱肿瘤相关抗原检测试剂盒
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CN105067731B (zh) * 2015-06-05 2017-06-16 中国农业科学院兰州兽医研究所 一种弓形虫感染后血清中生物标记物的筛选方法及筛选出的生物标记物的应用
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
WO2017096247A1 (en) 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
TWI752930B (zh) * 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
US20200182884A1 (en) * 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
EP3573997A4 (en) * 2017-01-24 2020-12-09 Abexxa Biologics, Inc. METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2018217852A1 (en) * 2017-05-23 2018-11-29 Gettysburg College Crispr based tool for characterizing bacterial serovar diversity
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
WO2021176352A2 (en) * 2020-03-03 2021-09-10 Tarek Mohammad Custommune: a web tool for designing personalized and population-targeted peptide vaccines
WO2024050547A2 (en) * 2022-09-02 2024-03-07 Hunterian Medicine Llc Compact bidirectional promoters for gene expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4423392A1 (de) * 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
WO1997041440A1 (en) * 1996-04-26 1997-11-06 Rijksuniversiteit Te Leiden Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
WO2000075336A2 (fr) * 1999-06-03 2000-12-14 Biovector Therapeutics Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
US5093242A (en) * 1986-10-02 1992-03-03 Massachusetts Institute Of Technology Methods of generating desired amino-terminal residues in proteins
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
AU611263B2 (en) * 1988-02-12 1991-06-06 Commonwealth Scientific And Industrial Research Organisation Pox virus vectors
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2072620C (en) 1989-11-03 2007-06-12 Donald L. Morton Urinary tumor associated antigen, antigenic subunits uses and methods of detection
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5744316A (en) * 1992-12-22 1998-04-28 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6299295B1 (en) 1997-07-03 2001-10-09 Matsushita Electric Industrial Co., Ltd. Ink jet printing head having ink chambers arranged in succession by lamination
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US20040236514A1 (en) * 2001-12-13 2004-11-25 Lee Stephen C. Controlling distribution of epitopes in polypeptide sequences

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4423392A1 (de) * 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
WO1997041440A1 (en) * 1996-04-26 1997-11-06 Rijksuniversiteit Te Leiden Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
WO2000075336A2 (fr) * 1999-06-03 2000-12-14 Biovector Therapeutics Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination
WO2000075181A1 (fr) * 1999-06-03 2000-12-14 Biovector Therapeutics FRAGMENTS PROTEIQUES POLYEPITOPIQUES DE LA PROTEINE Nef DE HIV, LEUR OBTENTION ET LEURS UTILISATIONS NOTAMMENT EN VACCINATION

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Melief et al. (see ISR) *
Morel et al. (see ISR) *
Thomson et al. (see ISR) *

Also Published As

Publication number Publication date
AU2010251790B2 (en) 2013-02-07
EP2248910A1 (en) 2010-11-10
DK1276896T3 (da) 2010-10-18
AU2001257410B9 (en) 2006-10-05
WO2001082963A2 (en) 2001-11-08
ES2347762T3 (es) 2010-11-04
AU2001257410B2 (en) 2006-08-24
US20070269464A1 (en) 2007-11-22
NZ521715A (en) 2008-01-31
CA2405363A1 (en) 2001-11-08
EP1276896B1 (en) 2010-07-21
AU2010251790A1 (en) 2011-01-06
CN1440462A (zh) 2003-09-03
HK1053333A1 (en) 2003-10-17
EP2278023A1 (en) 2011-01-26
JP2003535824A (ja) 2003-12-02
DE60142615D1 (de) 2010-09-02
WO2001082963A3 (en) 2002-04-11
ATE474931T1 (de) 2010-08-15
EP2278024A1 (en) 2011-01-26
EP1276896A2 (en) 2003-01-22
AU5741001A (en) 2001-11-12

Similar Documents

Publication Publication Date Title
AU2001257410B9 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
US20120010384A1 (en) Epitope synchronization in antigen presenting cells
AU2001257410A1 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
US6861234B1 (en) Method of epitope discovery
EP2470200B1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP2155780B1 (en) P53 peptide vaccine
US20030138808A1 (en) Expression vectors encoding epitopes of target-associated antigens
JP2009279006A (ja) 抗原提示細胞におけるエピトープ同調
Minev Melanoma vaccines
EP3079716B1 (en) Multi-epitope tarp peptide vaccine and uses thereof
AU2006246500B2 (en) Epitope synchronization in antigen presenting cells
US20050033023A1 (en) PTH-rP related peptide cancer therapeutics
HK1153782A (en) Epitope cluster from melan-a/mart-1 for the induction of anti-tumor immunogenicity
HK1053333B (en) Epitope synchronization in antigen presenting cells
HK1153512A (en) Epitope cluster from ny-eso-1 for the induction of anti-tumor immunogenicity
HK1150633A (en) Epitope synchronization in antigen presenting cells
Arlen et al. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer
Parkinson The development of novel immunotherapy strategies for prostrate cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MANNKIND CORPORATION

Free format text: FORMER APPLICANT(S): CTL IMMUNO THERAPIES CORP.

SREP Specification republished
TH Corrigenda

Free format text: IN VOL 20, NO 32, PAGE(S) 3187 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME MANNKIND CORPORATION, APPLICATION NO. 2001257410, UNDER INID (54), CORRECT THE TITLE TO METHOD OF IDENTIFYING AND PRODUCING ANTIGEN PEPTIDES AND USE THEREOF AS VACCINES

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired